STRATEC’s Birkenfeld site suffers water damage

Birkenfeld, June 5, 2013

STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) reported today that the heavy rains that fell in the past few days have caused surface water to damage several buildings at STRATEC’s complex in Birkenfeld, Germany.

Although the clean-up process has now been largely completed, business operations at the Birkenfeld site are likely to be affected for a period of several weeks. Particularly, some delays in services such as project deliverables are to be expected.

The aforementioned service delays will primarily affect the “Prototyping” and “Reliability Testing” divisions, leading to postponed recognition of revenue that could be as high as € 3 million. The impact on revenue and earnings will mainly be felt the in the second quarter of 2013. Due to the current uncertainties, the publication of the financial guidance for 2013 and subsequent years, which was slated for June 2013, will now coincide with the publication of the half-yearly results for 2013 scheduled to take place on July 23, 2013.

An insurance claim will be made for the full extent of material and business interruption damages.

About STRATEC

STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, and are a constituent of the Deutsche Börse TecDAX.


Further information can be obtained from:

STRATEC Biomedical AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Phone: +49 7082 7916 190
Fax: +49 7082 7916 999
Email:ir@stratec.com